Feeds:
Posts
Comments

Personalized Medicine been Positively affected by FDA Drug Approval Record

Reporter: Aviva Lev-Ari, PhD, RN

FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes

By Anna Edney and Michelle Cortez

June 20, 2017, 10:41 AM EDT June 20, 2017, 3:02 PM EDT

https://www.bloomberg.com/news/articles/2017-06-20/fda-moves-to-clear-path-for-drugs-aimed-at-cancer-causing-genes

 

 

‘Landmark FDA approval bolsters personalized medicine’

PMC – An Op-Ed in STAT News

by Edward Abrahams

June 21, 2017

Our understanding of cancer has been morphing from a tissue-specific disease — think lung cancer or breast cancer — to a disease characterized more by specific genes or biomarkers than by location. A recent FDA decision underscores that transition and further opens the door to personalized medicine.

Two years ago, the director of the FDA’s Office of Hematology and Oncology Products told the Associated Press that there was no precedent for the agency to approve a drug aimed at treating tumors that generate a specific biomarker no matter where the cancer is in the body. Such a drug had long been seen as the epitome of personalized medicine. But with the rapid pace of progress in the field, director Dr. Richard Pazdur said, such an approval could one day be possible.

That day has arrived.

In a milestone decision for personalized medicine, the FDA approved Merck’s pembrolizumab (Keytruda) late last month for the treatment of tumors that express one of two biomarkers regardless of where in the body the tumors are located. The decision marks the first time FDA has approved a cancer drug for an indication based on the expression of specific biomarkers rather than the tumor’s location in the body.

Keytruda is designed to help the immune system recognize and destroy cancer cells by targeting a specific cellular pathway. The FDA notes that the two biomarkers — microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) — affect the proper repair of DNA inside cells.

The approval represents an important first for the field of personalized medicine, which anticipates an era in which physicians use molecular tests to classify different forms of cancer based on the biomarkers they express, then choose the right treatment for it. In contrast to standard cancer treatments, which are given to large populations of patients even though only a fraction of them will benefit, Keytruda was approved only for the 4 percent of cancer patients whose tumors exhibit MSI-H or dMMR mutations. That may help the health system save money by focusing resources only on patients who are likely to benefit from Keytruda.

Such “personalized” strategies now dominate the landscape for cancer drug development. Personalized medicines account for nearly 1 of every 4 FDA approvals from 2014 to 2016, and the Tufts Center for the Study of Drug Development estimates that more than 70 percent of cancer drugs now in development are personalized medicines.

While this is encouraging, the U.S. research, regulatory, and reimbursement systems aren’t aligned to stimulate the development of personalized medicines, and may even deter progress.

The Trump administration’s proposal to cut biomedical research spending at the National Institutes of Health by 18 percent in fiscal year 2018, for example, would undermine its ability to fund more studies like the National Cancer Institute’s Molecular Analysis for Therapy Choice (MATCH) trial, which is designed to test targeted therapies across tumor types.

While the regulatory landscape for these targeted medicines is clear, the path to market for the molecular tests that do the targeting is not. That uncertainty continues to stifle investment in the innovative tests that make personalized medicine possible. The result is a clinical environment in which the patients who could benefit from personalized medicines are often never identified because the necessary tests aren’t available to them.

Finally, increasing pressure on pharmaceutical and diagnostic companies to decrease prices without considering their value to individual patients and the health system could also deter investment in innovative solutions that address unmet medical needs, particularly for smaller patient populations.

Confronted with unprecedented opportunities in personalized medicine, policymakers would do well to ensure that our research, regulatory, and reimbursement systems facilitate the development of and access to these promising new therapies. Only then can we ensure that Keytruda’s groundbreaking approval represents the beginning of a new era that promises better health and a more cost-effective health system.

Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition.

 

 

 

SOURCE

From: <cwells@personalizedmedicinecoalition.org>

Date: Wednesday, June 21, 2017 at 1:38 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: PMC in STAT: “Landmark FDA Approval Bolsters Personalized Medicine”

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

Author and Editor-in-Chief: Aviva Lev-Ari, PhD, RN, 

Nominee for 2018 Yidan Foundation Prize for Medical Education Content Development

 

Aviva Lev-Ari on 9/2009

Recollections: My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

 

Updated on 4/2/2018

Question: WHAT MAKES us so unique

Answers: 1,2,3,4

1. Sustainability

The books are online topics in medical science, diagnostics and therapy that are maintained by updating the chapter material in the Biomed e-series directly pertaining to the chapter content that is directly available from the e-series online. The Chapters are compiled from detailed review of the available literature, and the content of each book is related to current concepts researched and coordinated for the published work. One of the Research Categories: Interviews with Scientific Leaders includes in its growth plan the option of Podcasts which is an Audio Media component to supplement the video media component which is used extensively in the BioMed e-Series

How we accomplish the Sustainability goal:

  • Online continuing updates are made to articles in the Journal
  • Each e-Book has an abbreviated electronic Table of Contents which consists of LIVE LINKS for each article in an e-Book to the article in the Journal. eReaders of the e-Books clicks on the link and get the most updated State of Science for each topic in the e-books.
  • Journal Ontology is a relational and hierarchical knowledge base allowing for expansion of the content creation process on these two dimensions and is not limited to these two. For example: One of the Research Categories: Interviews with Scientific Leaders includes in its growth plan the option of Podcasts which is an Audio Media component to supplement the video media component which is used extensively in the BioMed e-Series.

2. A Future-Oriented Vision

Cutting edge research is the content of a research reservoir that allows for the creation of up-to-date content, and which supports new developments as they arise. The cutting edge concepts are reviewed in concordance with timely conferences on topical material. These conferences are also recorded and conveyed in the related documents. Since 2013, International leading Breakthroughs in BioTechnology Conferences are covered in Real Time by Dr. Aviva Lev-Ari on PRESS Pass.

How we accomplish the Future-Oriented Vision goal:

  • The Intellectual Property Vault (N= +5,200) has the potential of being used for creation of New Titles for New e-Books. It is a reservoir of Ideas in the form of Research Categories populated by Scientific Curations
  • Online reach is growing and is driven by cutting edge subject matters added on a continuous basis to the Intellectual Property Vault
  • Innovations in Drug Discovery and Drug Delivery are covered in Real Time, on average up to 12 per year
  • See Section
  • In 2018, the list of International leading Breakthroughs in BioTechnology Conferences that will be covered in Real Time by Aviva Lev-Ari, PhD, RN includes the following, as confirmed on 1/2018, more will be confirmed in during 2018:

AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA

https://pharmaceuticalintelligence.com/2018/04/02/ai-machine-learning-in-clinical-trials-april-12-2018-pfizer-innovation-research-lab-cambridge-ma/

2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts, Westin Copley Place

https://pharmaceuticalintelligence.com/2018/01/18/2018-annual-world-medical-innovation-forum-artificial-intelligence-april-23-25-2018-boston-massachusetts-westin-copley-place/

12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

https://pharmaceuticalintelligence.com/2018/01/18/12th-annual-us-india-biopharma-healthcare-summit-may-8-2018-marriott-cambridge/

The 14th Annual Personalized Medicine Conference, November 13 – 15, 2018, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston

http://www.personalizedmedicinecoalition.org/Events

3. Transformation

  • We Focus on Transformative subject matters:
  • Examples: We published e-Books on
  1. Regenerative and Translation Medicine
  2. Next Generation Sequencing in Genomics (work-in-progress)
  3. Epigenetics, Genetics and Genomics
  4. Precision Medicine & Voices of Patients

These contents are timely and among other material are subject to periodic updating. The reports are subject to a rigorous process of investigation, up-to-date reporting, analysis, and interpretation. The curation is done by experts with a perspective on the field allowing for the creation of the scientific CONTEXT that unifies the concept evolution with the breakthrough presented at hand and the future implications to be anticipated.

How we accomplish the Transformation goal:

  • Methodology of Curation is Transformative as a Medium for written scientific communication: Synthesis, Analysis and Interpretation
  1. Experts, Authors, Writers add their depth in thinking on subjects to the breath of materials selected by their expertise to be forming new curations or updating existing ones
  2. It is transformative in its capacity to accelerated diffusion of scientific innovations process, the curation is done by experts with a perspective on the field allowing for the creation of the scientific CONTEXT that unifies the concept evolution with the breathrough presented at hand and the future implications to be anticipated. In an analogy, it is an expressive medium for creative exposition of multiple combinations of Past, Present, Future tenses in grammar, when the presentation is on the continuous process of discovery.

4. Innovation & Creativity

The content available provides commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN. In addition, it provides a knowledge architecture that features Innovative ideas that tackle pressing challenges in the field of Medical Education. Content includes methodology development for: Curation of Scientific Findings by Experts; Actual Curations, “Mapping” the Medicine Disciplines; Exposition of the Scientific Frontier in Five Specialties in Medicine, and then also pressing challenges in the field of Medical Education such as the Digital Information Explosion in the fields of Life Sciences and Medicine; and finally the Pursuit of Excellence in Content Creation by Curation Methodology for Medical subject matters in multiple areas of the Health Care field.

How we accomplish the Innovation & Creativity goal:

  • Seven factors are presented, below

F1        What was accomplished by Development of the Curation Methodology

F2        Method Selection of the Open Access Journal Publishing Medium

F3        Selection of electronic Books vs Hardcover or Softcover type of product

F4        Examples of Creative Article Titles

F5        Examples of Creative eTOCs

F6        Examples of Hierarchical Ontologies created by Experts/Authors/Writers for selected Categories of Research with +500 Articles

F7.       Articles of Note on selective Research Topic @PharmaceuticalIntelligence

The Body of Work

 

A. Publication of the BioMedical e-Books e-Series, 2013 – Present

This is the link to Amazon.com, Kindle Store’s Page for the 13 volumes published till 12/30/2017

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

 

These are the links to Amazon.com, Kindle Store’s Page for each volume

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

http://www.amazon.com/dp/B071VQ6YYK

https://www.amazon.com/dp/B075CXHY1B

https://www.amazon.com/dp/B076HGB6MZ

https://www.amazon.com/dp/B078313281

https://www.amazon.com/dp/B078QVDV2W

 

B. BioMedical e-Books e-Series: Multiple Volumes in Five e-Series with Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

  • Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series

https://pharmaceuticalintelligence.com/biomed-e-books/commentaries-on-each-volumes-contribution-to-medical-education-by-l-h-bernstein-md-fcap-and-aviva-lev-ari-phd-rn-biomedical-e-books-e-series-multiple-volumes-in-five-e-series/

 

C.      electronic Table of Contents (eTOCs) of each Volume in the SIXTEEN-Volume BioMed e-Series

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/

Analytics for the BioMed e-Series based on:

  1. Number of Articles per Volume
  2. E-Readers per Article
  3. Volume e-Impression since DATE of Publication [Summation of 2, above for all articles inside each Volume, before it was inside an e-Book and after the DATE of publication [Product details per Volume in attachment – Five e-Series – several Volumes per e-Series] PENDING

 

D.         Innovative ideas that tackle pressing challenges in the field of Medical Education: Knowledge Architecture

D1        Methodology Development for Content Creation targeted at Medical and Life Sciences Education (Curation of Scientific Findings by Experts)

D2        Methodology Development for Scientific Inquiry in Medicine: Case Studies in a Medical Specialty – Application of the Methodology of Curation to Case Studies – Published as a Book, 2015

D3        Methodology Development for Mapping the Medicine Discipline for Education

D4        Methodology Development for Exposition of the Scientific Frontier in Five Specialties in Medicine (D4.1, D4.2, D4.3, D4.4, D4.5).

 

E.         Innovative ideas that tackle pressing challenges in the field of Medical Education: Digital Information Explosion in the fields of Life Sciences and Medicine

E1        Open Access Scientific Journal Launch in Biomedicine and Site Statistics:

+1.3 Million eReaders and eSubscribers

E2        Journal Ontology for Knowledge Architecture – +600 Categories of Research

E3        Intellectual Property Vault: Knowledge Base of +5,200 Scientific articles applying the Curation of Scientific Findings Methodology

E4        Scientific Agora: Multi Scientific Comment exchanges between e-Readers Scientists and LPBI’s Scientists/Experts/Authors/Writers

E5        Real Time (RT) Press Coverage of Leading Conferences in BioMedicine: RT Methodology and the Archive

E6        Impact of E5 on E3

 

F. Innovation & Creativity Demonstrated in the Pursuit of Content Creation by Curation Methodology for Medical Education. For us perfection of the application process of curation methodologies in Medicine is a pursuit of excellence in the creation of content in Life Sciences and in Medicine.

F1        What was accomplished in five years by Development of the Curation Methodology

F2        Method Selection of the Open Access Journal Publishing Medium

F3        Selection of electronic Books vs Hardcover or Softcover type of product

F4        Examples of Creative Article Titles

F5        Examples of Creative eTOCs

F6        Examples of Hierarchical Ontologies created by Experts/Authors/Writers for selected Categories of Research with +500 Articles

F7        Articles of Note in selective Research Topic @PharmaceuticalIntelligence

 

G.         Editor-in-Chief’s Roles and Accomplishments

G1        Curation Methodology Development

G2        Content Creation and Key Opinion Leader (KOL) Recognition

Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Aviva Lev-Ari, PhD, RN

G2.1         Volume of Articles in the Journal and in the 16 Volume-BioMed e-Series

G2.2         Digital Presence

G2.3         Digital KOL Parameters

G3        Team building: Editors and Expert, Authors, Writers

G4        Book Title Generation and Cover Page Design

G5        Style Setting: Instruction manual for Journal, Articles, Books

G6        Annual Workflow Management of Multiple eTOCs – Multi-year Book Publishing Scheduling Plan, 2013 – Present

 

In this article I cover the Business Synopsis and the following Four Parts of the Business:

Part 1: The Vision

Part 2: Scientific Journal – Site Statistics on 6/20/2017

Part 3: BioMed e-Series

Part 4:  Real Time (RT) Press Coverage  of 50 Biotech Top Conferences

 

Synopsis

Dr. Aviva Lev-Ari, PhD, RN has launched in 4/2012 the PharmaceuticalIntelligence.com an Internet-based website as an educational Open Access Online Scientific Journal. On 10/2012 Dr. Lev-Ari, launched a BioMed e-Series of electronic Book in Medicine and Life Sciences which use the Kindle Direct Publishing platform for book publishing by Amazon.com.

The books having evolved for six years from specifically identified topics in Medicine and Biomedical Sciences, including molecular biology, genomics, pharmaceutics and pathophysiology. There have been a number of contributors with the necessary professional competences. The books have been organized into five series that include cardiovascular, genomics, proteomics, pharmacotherapy, cancer and carcinogenesis, infectious disease and immune mechanisms. In addition to these basic disciplines for study there are also important deliberations on the history of medicine and physiology and a focus on the impact of disease on human experience in three books of Series E: Patient-centered Medicine.

The work involved in the writing took many hundreds of hours of study and preparation. These sources have considerable electronic readership (+1.3Million) and have a potential for growing use in teaching of medical students, advanced undergraduate and graduate students in Medical Sciences. Currently, two e-Books are used in curriculum development in Medical Schools in the US. An outreach plan for Deans of Medical Schools and Oncologists and Cardiologists in the Community Hospitals and Clinics is in the making.

The XXXXXXX Prize is awarded for outstanding contributions to education. In this respect the contributions of PharmaceuticalIntelligence.com current and authentic documents is deserving of consideration. Nomination is submitted for recognition as a means in tackling challenges in the field of MEDICAL education, and especially the “Sixteen Volumes in Medicine and Life Sciences” which are LPBI Group’s BioMed e-Series, an initiative of innovative ideas and development of curation methodologies for scientific contents. The BioMedical e-Books e-Series, 2013 – present, includes Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN. In addition, there is supporting material for an understanding of the role played by electronic Scientific Publishing in mastering the continued progress in Medical Sciences for the electronic exposition of the process used in new scientific content creations. These topics are fully covered in the BioMed e-series. Volume Two in Series A is dedicated to the Curation methodology of scientific findings.

Highlights

  • Interdisciplinary Journal covers interfaces of six domains

(Life sciences, Pharmaceuticals, Medicine, Healthcare Policy, Biotech Intelligence and Medical Devices)

  • Curations of Scientific Findings of peer reviewed articles in top three journals in each of the Six domain
  • Curations written on a multi-Authoring platform by MDs, MD/PhDs, PharmD and PhDs, all 15 years after graduation of the advanced degree program, and each has a publication list before joined my team – they write clinical and medical interpretations of the scientific frontier as evidenced in the Scientific Finding section of published articles in Cell, Nature, Science, NEJM, other top journals in these six domains.
  • Volume, ~5,150 Scientific articles, +500 categories of Research defining the Journal Ontology, 9,500 tags, 7,300, scientific comment on the articles submitted and exchange recorded between the Scientific community and our Team members
  • Top two articles >25,000 eReaders
  • Clicks on two Top Authors: >551,000
  • from NIH +3,700 hits
  • 2250 Journal subscribers by e-mail
  • +6,200 Biotech Executive following up on LinkedIn
  • BioMed e-Series: 16 volumes, 13 on Amazon.com

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

  • In House Developed Methodology for Real Time Press Coverage of Biotech Top International conferences – selective  topics covered at conferences lead to NEW Curations in the Journal

 

Part 1: The Vision

https://pharmaceuticalintelligence.com/vision/

Part 2: Scientific Journal – Site Statistics on 4/2/2018

https://pharmaceuticalintelligence.com/

1,407,787 Million eReaders on WordPress.com in 4/2018

Best ever daily views

2,508 views

Our DOMAINS in Scientific Media

I.  Pharmaceutical: Biologics, Small Molecules, Diagnostics

II.  Life Sciences: Genomics and Cancer Biology

III.  Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology: Metabolomics, Immunology

IV. Biomedicine, BioTech, and MedTech (Medical Devices)

V.  HealthCare: Patient-centered Medicine and Personalized/Precision Medicine

 

All time

1,239,246 eReaders on 6/25/2017 

on 4/2/2018

  • 1,407,787 eReaders & 
  • 2,295 Subscribers by e-mail
  • 7,283 Scientific comments
  •  5,291 Scientific Articles
  • 634 Categories of Research – Journal Ontology
  • 9,782 Tags

Followers (includes Publicize)

788 Twitter

699 Facebook

67 Tumblr

All Time

Top Posts >3,000 Views for all days ending 2018-04-02 (Summarized)

Title Views
Home page / Archives More stats 535,337
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? More stats 16,243
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) More stats 11,938
Recent comprehensive review on the role of ultrasound in breast cancer management More stats 9,675
Paclitaxel vs Abraxane (albumin-bound paclitaxel) More stats 9,376
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care More stats 6,141
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) More stats 5,992
Our TEAM More stats 5,979
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications More stats 4,833
Akt inhibition for cancer treatment, where do we stand today? More stats 4,447
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses More stats 3,995
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I More stats 3,805
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation More stats 3,587
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad More stats 3,582
Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms More stats 3,534
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo More stats 3,329
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets More stats 3,252
Founder More stats 3,243
BioMed e-Series More stats 3,170
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology More stats 3,129
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules More stats 3,037

Top Posts >3,000 Views for all days ending 2017-06-20 (Summarized)

Clicks for all days ending 2018-04-02 (Summarized) – All Time

URL Clicks
WordPress.com Media 38,388
commons.wikipedia.org 6,447
http://www.ncbi.nlm.nih.gov 4,036
en.wikipedia.org 3,292
http://www.nature.com 3,139
dx.doi.org 1,818
http://www.scoop.it 1,316
pharmaceuticalintelligence.wordpress.com 749
gravatar.com 703
http://www.sciencedirect.com 645
http://www.fda.gov 613
http://www.fiercepharma.com 552
apps.societyforscience.org/intelisef2012/project.cfm?PID=ME028&CFID=28485&CFTOKEN=10931553 550
http://www.cancer.gov 456
informahealthcare.com 413
ars.els-cdn.com 406
http://www.hindawi.com 367
http://www.youtube.com 361
http://www.medscape.com 353
http://www.nejm.org 310
http://www.linkedin.com 300

Referrers for all days ending 2018-04-02 (Summarized) – All Time

Referrer Views
Search Engines   742,459
linkedin.com 25,349
Facebook 7,662
lnkd.in 6,289
scholar.google.com 4,440
Twitter 3,363
android-app 1,847
investorshub.advfn.com 1,050
WordPress Dashboard 900
scoop.it 826
mail.yahoo.com 781
scholar.google.co.in 630
scholar.google.co.uk 584
WordPress.com Reader 555
avanza.se 401
correio.portugalmail.pt/imp/ 381
scholar.google.co.jp 349

 

Content

Top Authors for all days ending 2018-04-02 (Summarized) – All Time

Author Views
2012pharmaceutical   359,700
larryhbern 258,904
tildabarliya 53,989
sjwilliamspa 46,989
Dror Nir 28,039
Dr. Sudipta Saha 25,298
ritusaxena 16,060
Demet Sag, Ph.D., CRA, GCP 14,927
aviralvatsa 8,437
zraviv06 8,202
Gail S Thornton 5,904
zs22 3,996
danutdaagmailcom 3,594
anamikasarkar 3,380
Alan F. Kaul, PharmD., MS, MBA, FCCP 2,205
pkandala 2,179
Aashir Awan, Phd 2,006
Irina Robu 1,880
jdpmd 1,639
megbaker58 1,479
S. Chakrabarti, Ph.D. 745
Ed Kislauskis 651
David Orchard-Webb, PhD 579
howarddonohue 552
stuartlpbi 490
marzankhan 464
evelinacohn 392
apreconasia 365
anayou1 238
jukkakarjalainen 230
Dr.Sreedhar Tirunagari 162
lmulligan13gmailcom 147
gerag2015 125

Graphics for 4/2012 to 3/10/2015

Part 3: BioMed e-Series

  • The Methodology of Co-Curation


Image Source: Original Graphic Conceptualization of the Co-Curation Concept by Stephen J Williams, 3/10/2015

Titles in the BioMed e-Series: 16 e-Books in Medicine and Life Sciences

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

In each e-Book: Curations and Scientific reports by Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-aviva-lev-ari-phd-rn/

 

13 results for Kindle Store :

“Aviva Lev-Ari”

  • The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures ... E: Patient-Centered Medicine Book 1)

    The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures … E: Patient-Centered Medicine Book 1)

    Oct 16, 2017 | Kindle eBook

    by Larry H. Bernstein and Aviva Lev-Ari
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Amazon’s Aviva Lev-Ari Page

    Discover books, read about the author, find related products, and more.More about Aviva Lev-Ari
  • The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications: VOLUME 2: Infectious Diseases and Therapeutics and VOLUME 3: The ... (Series D: BioMedicine & Immunology)

    The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications: VOLUME 2: Infectious Diseases and Therapeutics and VOLUME 3: The … (Series D: BioMedicine & Immunology)

    Sep 4, 2017 | Kindle eBook

    by Larry H. Bernstein and Aviva Lev-Ari
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    May 13, 2017 | Kindle eBook

    by Larry H. Bernstein and Demet Sag
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Jun 20, 2013 | Kindle eBook

    by Margaret Baker PhD and Tilda Barliya PhD
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders (Series E)

    Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders (Series E)

    Dec 9, 2017 | Kindle eBook

    by Larry H. Bernstein and Aviva Lev-Ari
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Nov 28, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Jul 21, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Aug 10, 2015 | Kindle eBook

    by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Dec 26, 2015 | Kindle eBook

    by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Nov 22, 2015 | Kindle eBook

    by Sudipta Saha PhD and Ritu Saxena PhD
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Medical 3D BioPrinting – The Revolution in Medicine Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices (Series E: Patient-Centered Medicine Book 4)

    Medical 3D BioPrinting – The Revolution in Medicine Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices (Series E: Patient-Centered Medicine Book 4)

    Dec 30, 2017 | Kindle eBook

    by Larry H. Bernstein and Irina Robu
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Nov 29, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC
  • Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Dec 26, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Ritu Saxena PhD
    Subscribers read for free.
    Get it TODAY, Apr 2
    Sold by: Amazon Digital Services LLC

Forthcoming e-Books in 2018 & 2019

https://pharmaceuticalintelligence.com/biomed-e-books/

Series C, Volume Two was published in 2017 !!!

Work-in-Progress:

Series A, Volume 5 and Volume 6, and

Series B, Volume 2

 

 

 

Part 4: Real Time Coverage of 50 Biotech Top Conferences

https://pharmaceuticalintelligence.com/press-coverage/

 

Other related articles to e-Scientific Publishing include the following: 

·       PharmaceuticalIntelligence.com –  A Case Study on the LEADER in Curation of Scientific Findings

Author: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/06/29/pharmaceuticalintelligence-com-a-case-study-on-the-leader-in-curation-of-scientific-findings/

·    Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson

Curator: Stephen J Williams, PhD

https://pharmaceuticalintelligence.com/2014/07/17/scientific-curation-fostering-expert-networks-and-open-innovation-lessons-from-clive-thompson-and-others/

·       Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

Editor-in-Chief http://pharmaceuticalintelligence.com: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/05/06/case-studies-of-innovations-in-electronic-scientific-publishing-esp-marketing-econtent-curation-methodology-categories-of-research-functions-interdisciplinary-conceptual-innovations-by-cross-sec/

  • FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

·       Inevitability of Curation: Scientific Publishing moves to embrace Open Data, Libraries and Researchers are trying to keep up

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2015/02/19/inevitability-of-curation-scientific-publishing-moves-to-embrace-open-data-libraries-and-researchers-are-trying-to-keep-up/

·       The e-Factor in Curation of Scientific Findings

Curator: Aviva Lev-Ari, PhD, RN

https://www.linkedin.com/pulse/e-factor-curation-scientific-findings-aviva-lev-ari-phd-rn/

·       Power of Analogy: Curation in Music, Music Critique as a Curation and Curation of Medical Research Findings – A Comparison

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/02/11/power-of-analogy-curation-in-music-music-critique-as-a-curation-and-curation-of-medical-research-findings-a-comparison/

  • Three Genres in e-Scientific Publishing AND Three Scientists’ Dilemmas

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/06/28/three-genres-in-e-scientific-publishing-and-three-scientists-dilemmas/

·       e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Originally published on 2/6/2017

Author and Editor-in-Chief: Aviva Lev-Ari, PhD RN

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

 

Articles in each e-Book in the BioMed e-Series

 

 

Success of the life sciences industry in Massachusetts: Governor Charlie Baker – A new 5 year, $500 million investment

Reporter: Aviva Lev-Ari, PhD, RN

 

We are thrilled to share this exciting news with you. Earlier today, Governor Charlie Baker announced he will be filing legislation to establish the next phase of the life sciences initiative with a new 5 year, $500 million investment. As the original 10-year, $1 billion program expires next year, this action is critical to the continued success of the life sciences industry in Massachusetts, and to patients around the world who continue to seek new treatments and cures they need and deserve.

As noted by the Governor’s office, the focus of this next phase of the life science initiative will include strengthening investments in human capital to fortify the state’s skilled workforce pipeline, expanding opportunities for companies to access both private investment capital and dynamic public infrastructure resources, developing new scientific innovations that deliver higher outcome, affordable therapies to patients, and leading the convergence revolution in digital health, biopharma, medical devices and engineering.

Over the last nine years the life science initiative and the Massachusetts Life Sciences Center has cemented Massachusetts as the life sciences leader nationally and across the world. In Cambridge and Boston we have the best, most dense biotech cluster in the world. In Worcester, we have a cluster which can stand on its own as one of the biggest in the country. And in the northern and southern parts of the state, jobs in the life sciences are growing faster than anywhere else in the state. With a $147,000 average salary, $9 billion in total payroll, and an expected 11,600 new jobs over the next five years, the life sciences is a huge economic engine for this state. With today’s announcement, we know that companies will continue to come and expand in Massachusetts for years to come and make our economy grow. 

Most importantly, the continuation of the life sciences initiative ensures that patients across the world will continue to receive the breakthrough cures and treatments that are being developed every day in Massachusetts. 

Today’s an exciting day for Massachusetts. We’re thrilled to be part of it.

– Bob Coughlin

 

SOURCE
From:
MassBio <communications@massbio.ccsend.com> on behalf of MassBio <robert.coughlin@massbio.org>

Reply-To: <communications@massbio.org>

Date: Monday, June 19, 2017 at 1:06 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Breaking News: Gov. Baker Announces Next Phase of Life Sciences Initiative

Molecular Pathogenesis of Progressive Lung Diseases

Author: Larry H. Bernstein, MD, FCAP

 

Abstract

The lung and its airways are constantly exposed to the air we breath, its contaminants, microparticulates (asbestose), and incidental microorganisms, such as viruses. These are sources of acute and chronic pulmonary diseases. Just as the lung remodels in normal growth and development, the lung remodels following acute injuries, but in the case of chronic conditions, the remodeling capacity is stressed. The lung is potentially stressed even without exposure to external contaminants or viruses. This stress is related to its normal function of gas exchange between oxygen and carbon dioxide across the alveolar wall. This involves a mechanism for tissue repair initiated by signaling pathways that are triggered in response to oxidative stress that result in a process called the unfolded protein response (UPR). The UPR does not necessarily lead to tissue damage. Damage only occurs when there is sustained stress that exceeds the ability of the tissue to repair the cellular framework. Here, we shall visit the underlying repair process that may be undermined in different lung diseases, all of which involve the inflammatory response, but not necessarily under the same course and conditions.

 

Introduction

The lung develops as an outpouching of the foregut and consists of the trachea and bronchi, and the alveoli. Air exchange occurs in the alveoli. In utero, the lungs are filled with fluid, and breathing occurs at the time of birth. When birth is premature, the surfactant produced by the alveolar lining cells that is necessary for passage of air into and expand the lungs may be insufficient, leading to alveolar collapse. Another problem may be neonatal hypertension. The discussion that follows will only deal with a common metabolic condition that underlies the conditions that underlie the development of chronic pulmonary diseases in the neonate and the adult.

The main feature of the alveoli is that they consist of a single layer of epithelium lining the airspaces beneath which lies a capillary, ideally suited for the exchange of O2 and CO2. There is a basement membrane between the epithelial cells and the capillaries. Two types of alveolar epithelial cells cover 90% of the airway surface. The alveolar type I epithelial cells (ATI), whose main function is gas interchange, are the larger flattened phenotype. Alveolar type II epithelial cells (ATII) are the most abundant epithelial cell type functioning to maintain the alveolar space by secretion of several types of surfactant proteins and other ECM components. There is also a basement membrane beneath the epithelium to be considered. Secretory Clara and goblet cells, ciliated, basal and neuroendocrine cells are also found in the tracheo-bronchial pseudostratified epithelium. Ciliated and secretory cells are involved in clearing the airway passages from microorganisms, air pollutants and other inhaled pathogens. Mucous and goblet cells secrete mucous into the apical surface of the epithelium, which traps foreign particles. These are then cleared out by the action of ciliated cells.

In cellular senescence there are secretory phenotypes that produce pro-inflammatory and pro-fibrotic factors. In the case of subepithelial fibrosis immune cells, like macrophages and neutrophils as well as activated myofibroblasts populate the subcellular matrix and release of pro-fibrotic transforming growth factor beta and continuous deposition of ECM stiffens the basement membrane. This is accompanied by interstitial fibrosis (1).

The remainder of this review will consider how the lung reacts to stresses that may be functionally inherent, genetic mediated, environmental, or virus. This requires an understanding of the UPR, a common mechanism for cellular repair in response to oxidative and nitrosative stress, which is the common mechanism for protecting the alveolar cell, but becomes pathogenic when the stress exceeds the clearance mechanism.

 

The unfolded protein response (UPR)

The mitochondria (mi) and the endoplasmic reticulum (ER) play key roles in the response to stress, and the mitochondria are also involved by way of signaling mechanisms. We shall begin by considering the ER role (ERUPR). The ER are tubular structures that have smooth and rough portions. The rough ER are essential for translation of the genetic code into an amino acid sequence. The smooth ER is involved in lipid synthesis, and other processes. Just as tRNAs are important building blocks for protein, microRNAs come into the picture as well. The microRNAs have a regulatory role in that they are noncoding, but they repress gene expression and thereby, protein homeostasis (protostasis) under the influence of ERUPR signaling. They have their expression under the influence of UPR signaling when there is oxidative/nitrosative stress (2).

The ER-induced ERUPR is mediated by three major ER-resident transmembrane sensors named PKR-like endoplasmic reticulum kinase (PERK), activating transcription factor 6 (ATF6a and isoforms), and inositol requiring enzyme 1 (IRE1a and isoforms)(2-4). BiP is an abundant ER chaperone that dissociates from these three sensors, leading to their activation of the ER stress response.

The first step is activation of IRE1a, which dimerizes, forms oligomers, and autophosphorylates. This results in a conformational change that activates RNAse. IRE1a RNAse excises a 26-nucleotide intron of the mRNA encoding the transcription factor X-box binding protein-1 (XBP1). This in turn is ligated resulting in a coding reading phase frame shift in the mRNA and leads to the expression of a more stable and active transcription factor, termed XBP1 spliced (XBP1s). XBP1s trans-activates target genes, which depends on the context of tissue and the stress stimuli. The targets of XBP1s are genes involved in protein folding, endoplasmic reticulum-associated degradation (ERAD), protein translocation to the ER, and protein secretion. IRE1a also signals through the assembly of many adapter proteins and regulators, referred to as the UPRosome, as well as control gene expression through ER stress-dependent XBP1 mRNA splicing (2-5)).

The ER is the site where protein is synthesis and maturation occurs. It is also where the transportation and release of correctly folded proteins together with the Golgi apparatus. ER dysfunction has been viewed in the context of adaptation to protein processing and folding in the ER lumen (3).

Activation of the UPR results in accumulation of reactive oxygen species (ROS) in cells devoid of PERK. ATF4 and PERK knockout cells require amino acid and cysteine supplementation. This is thought to be to replenish amino acids lost during secretion and to increase glutathione levels. ATF4 is essential for regulating amino acid metabolism and oxidative stress response. (In addition, PERK knockout cells cannot activate eIF2a dependent translational up-regulation of ATF4, and ATF4-/- cells lack ATF4 protein. ATF4 induces the transcription of genes involved in amino acid import, glutathione biosynthesis and resistance to oxidative stress (3).

NFD-kB is released from its inhibitor IkB as a result of PERK-mediated attenuation of translation. A variety of different genes involved in inflammatory pathways are expressed, such as those encoding the cytokines IL-1 and TNF-a, as NF-kB moves to the nucleus and switches on. Activated IRE1a recruits tumor necrosis factor-a (TNF-a)-receptor-associated factor 2 (TRAF2) in the second branch of the UPR. TRAF2 then activates JNK and IkB kinase (IKK). These are inflammatory kinases that phosphorylate and activate downstream mediators of inflammation. The third branch of the UPR, the ATF6 pathway, also activates NF-kB. The crosstalk between the three branches is evidenced by the spliced X-box binding protein 1 (XBP1s) and ATF4 both inducing production of the cytokines IL-8, IL-6, and monocyte chemoattractant protein 1 (MCP1) by endothelial cells. XBP1s and IFN-b are both initiated in IFN-b production when ER stress is combined with activation of Toll-like receptor (TLR) signaling and in IFN-a production by dendritic cells. ER calcium stores are mediated in calcium-dependent inflammatory responses that produce IL-8. The XBP1s expand the capacity of the ER for protein folding and results in the assembly of the metainflammasome. This protein complex integrates pathogen and nutrient sensing with ER stress, inflammatory kinases, insulin action, and metabolic homeostasis. The eIF2a kinase PKR (double-stranded RNA-activated protein kinase) is a core component of the metaflammasome which interacts directly with several inflammatory kinases such as IKK and JNK, insulin receptor signaling components such as IRS1, and the translational machinery via eIF2a (4).

The conformational alteration of IRE1 via phosphorylation which exposes the RNAse that removes an intron from XBP1 mRNA generates of a protein that is a transcriptional regulator of genes involved in protein folding and degradation, both necessary mechanisms needed to restore ER homeostasis. GRP78 dissociation activates PERK, which in turn phosphorylates eIF2a, an inhibitor of new protein translation and activator of the transcription factor ATF4. The phosphorylation of PERK observed in primary aveolar epithelial cells comes with significant increase in the expression of ATF4 (5).

ER stress-dependent activation of UPR-mediated ER Ca2+ store expansion (via XBP-1 mRNA splicing) is induced by inflammation. This response is coupled to amplification of Ca2+-dependent inflammation and may be beneficial or adverse for the airways. This depends on whether airways are competent to clear or are obstructed. In normal airways (competent to clear), the airway epithelial ER Ca2+ store expansion provides a beneficial response, and reverses the expanded ER Ca2+ stores back to normal levels. However, the airway epithelial ER Ca2+ store expansion-mediated amplification of airway inflammation may be maladaptive for CF and COPD airways. This results in persistent airway epithelial ER Ca2+ store expansion that leads to chronic airway inflammation (3).

XBP1s launches a transcriptional program to produce chaperones (such as Grp78) and proteins involved in ER biogenesis, phospholipid synthesis, ER-associated protein degradation (ERAD), and secretion alone or in conjunction with ATF6a, which are key regulators of the transcriptional response programs.

There are five proteins that have sequence similarity with ATF6a and are anchored to the ER and in response to activation by specific stimuli. They undergo regulated intramembrane proteolysis in the Golgi and subsequent translocation to the nucleus. They all have been implicated in the ER stress response due to their ability to respond to traditional ER stressors. They activate known UPR targets, or show activity at UPR response elements.

Activation of the third arm of the UPR through PERK results in phosphorylation of eukaryotic translational initiation factor 2a (eIF2a) converting eIF2a to a competitor of eIF2b, which then results in reduced global protein synthesis. PERK is one of four protein kinases that can mediate eIF2a phosphorylation; the other three kinases are double stranded RNA-activated protein kinase (PKR), GCN2 general control non-derepressible kinase 2 (GCN2), and heme-regulated inhibitor kinase (HRI)(4).

 

Oxidative stress

Several oxidants give rise to reactive oxygen species (ROS) by inflammatory and epithelial cells within the lung as part of an inflammatory-immune response. These interfere with protein folding in the ER and the compensatory response is the ‘‘unfolded protein response’’ (UPR). Superoxide radicals (O2 •−) can either react with nitric oxide (NO) to form highly reactive peroxynitrite molecules (ONOO) or are rapidly converted into hydrogen peroxide (H2O2) under the influence of superoxide dismutase (SOD) by activation of NADPH oxidase 2 (Nox2) on macrophages, neutrophils and epithelium. The non-enzymatic production of damaging hydroxyl radical (OH) from H2O2 occurs in the presence of Fe2+. Glutathione peroxidases (Gpxs) and catalase catalyze H2O2 to formH2O and O2. The ROS O2•−, ONOO, H2O2 andOH trigger extensive inflammation, DNA damage, protein denaturation and lipid peroxidation. Lipid peroxidation products are 8-isoprostane, 4-hydroxy-2-nonenal (4-OH-2-nonenal) and malondialdehyde (MDA)], LTB4, carbon monoxide and myeloperoxidase (MPO)(6).

 

Mitochondrial phase of UPR (mtUPR)

Mitochondria have a role in regulating alveolar epithelial cell (AEC) programmed cell death (apoptosis), and they are impaired by the generation of ROS, previously discussed. mtDNA encodes for 13 proteins, and that includes several essential for oxidative phosphorylation. The role of hemoglobin in O2/CO2 exchange given the redox state of iron, and the significant concentration of mitochondria in the AEC provides a suitable environment for the generation of ROS, which trigger an AEC mtDNA damage response and apoptosis (7). AEC mtDNA damage repair depends on 8-oxoguanine DNA glycosylase (OGG1) and mitochondrial aconitase (ACO-2), as they actively maintain mtDNA integrity. Reactive oxygen species (ROS)-driven mitochondrial metabolism is modulated by SIRTs. Indeed, SIRT3 is a mitochondrial deactylase linked to mitochondrial metabolism and mtDNA integrity. Moreover, it is known that there is crosstalk between mitochondrial ROS production, mtDNA damage, p53 activation, OGG1, and ACO-2 acting as a mitochondrial redox-sensor involved in mtDNA maintenance (7). Oxidative stress-induced mtROS induces mtDNA damage. It decreases the concentration of SIRT3, ACo-2 and mtOGG1 in AEC, and thereby causes a defective electron transport (ETC) that results in mitochondrial dysfunction, AEC apoptosis, and pulmonary fibrosis.

MtDNA encodes only 3% of mitochondrial proteins, and the rest are nuclear DNA proteins that are transported into the mitochondrion by transfer from the cytosol into the inner membrane. However, OGG1, ACO-2, mitochondrial transcription factor A (Tfam) are among those proteins encoded by nDNA essential for maintaining mtDNA integrity, as are those proteins involved in mtDNA repair. Nevertheless, mtDNA is ~50-fold more sensitive to oxidative damage because of proximity to the ETC, and are without histone protection, and repair mechanisms are limited. Consequently, stress-induced mtDNA damage has a mutation rate that is 10-fold greater than nDNA mtDNA damage. mtDNA mutations can then lead to mitochondrial dysfunction, including the collapse in the mitochondrial membrane potential (ΔΨm) and release of pro-apoptogenic agents (7).

The mitochondrial ETC generates hydroxyl radicals (HO), superoxide anions (O2•−), and hydrogen peroxide (H2O2) generated from redox-active ferrous (Fe2+) iron or contact with asbestos fibers that impair ETC function by decreasing SIRT3, ACo-2 and mtOGG1 in AEC, causing mtDNA damage creating energy imbalance leading to apoptosis. (Not shown. from Seok-Jo Kim, P Cheresh, RP Jablonski, DB Williams and DW Kamp. Int. J. Mol. Sci. 2015; 16: 21486-21519. http://dx.doi.org:/10.3390/ijms160921486)

 

AEC apoptosis and pulmonary fibrosis

AEC apoptosis is followed by pulmonary fibrosis (PF) because of mutation –related damage to AEC Type 2 (AT2) cells (i.e., surfactant C and A2 genes, MUC5b). Oxidative stress occurs in the majority of AT2 cells, many of them having shortened telomeres, and PF occurs in the underlying matrix (7). This is evidenced with activation by various fibrotic stimuli that stimulate pro-apoptotic Bcl-2 family members action (i.e., ROS, DNA damage, asbestos, etc.). The intrinsic apoptotic death pathway acting in mitochondria results in increased permeability of the outer mitochondrial membrane, reduced ΔΨm. This is accompanied by the release of apoptotic proteins, such as cytochrome c, that activate pro-apoptotic caspase-9 and caspase-3.

Pulmonary fibrosis is driven by PINK1 expression and AEC apoptosis. Pro-apoptotic Bim activation is associated with mitochondria-regulated apoptosis and fibrosis. In addition, mitochondrial quality control pathway disruptions lead to accumulation of mtDNA mutations. These mtDNA mutations may compromise ETC function, and they also drive AEC to aerobic glycolysis, associated with the lung cancer phenotype (7).

AEC mtDNA damage is modulated by p53 in the pro-fibrotic lung response (8). In this process, plasminogen activator inhibitor (PAI-1) promotes AEC apoptosis, and at the same time reduces fibroblast proliferation and collagen production. At the same time there is crosstalk between the p53-uPA fibrinolytic system in AT2 cells. A change in phenotype in lung fibroblasts and tissue injury includes lung fibrosis. This is brought on by mtDNA damage and a DNA damage-associated molecular pattern (DAMP) that activates innate immun responses, especially toll like receptor (TLR)-9 signaling (8).
Concurrently, ACO-2 can be relocated from the TCA cycle to the nucleosome to stabilize the mtDNA with subsequent removal of oxidized Aco-2 by Lon protease (9).

Consider the role that UPR plays a role in lung diseases caused by the expression of genetically mutated, misfolded proteins. In cystic fibrosis, The UPR in airway epithelial cells is activated by mutant cystic fibrosis transmembrane conductance regulator (CFTR) delta F508, which interferes with CFTR expression and activates the innate immune response. The UPR in AT2 induces AT2 apoptosis concomitant with epithelial–mesenchymal transformation and extracellular matrix production in mutant surfactant protein C–induced interstitial pulmonary fibrosis (IPF)(10). It also is assumed to play a role in the pathogenesis of COPD. Potential mechanisms that activate the UPR in AT2 cells include direct oxidation of client proteins or chaperones, impaired function of the proteasome or autophagosomes, and decreased expression of miRNAs.

 

Disease specific UPR involvement in pulmonary fibrosis

  • Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is characterized by repeated injury to the alveolar epithelium with loss of lung epithelial cells and abnormal tissue repair, which results in accumulation of fibroblasts and myofibroblasts, deposit of extracellular matrix components and distorted lung architecture (11). The expression of heme oxygenase-1, a critical defender against oxidative stress, is decreased in macrophages of idiopathic pulmonary fibrosis patients, suggesting an oxidant–antioxidant imbalance in the pathogenesis of idiopathic pulmonary fibrosis (12).

Epithelial apoptosis leads to the release of growth factors and chemokines, which recruit fibroblasts to the site of injury (fibroblastic foci). Thus, myofibroblasts proliferate and extracellular matrix is deposited continues unabated in IPF. The transformation of epithelial cells into mesenchymal cells is a process known as epithelial mesenchymal transition. It allows direct communication between cells, and may explain the buildup of myofibroblasts in interstitial pulmonary fibrosis (IPF). When the distal epithelium in the lung becomes injured the basement membrane loses its integrity. It has to re-epithelialize the surface. Growth factors locally produced can potentially recruit fibroblasts or myofibroblasts (11). TGFb
-/- mice are devoid of avb6 integrin. Hence, they are unable to activate latent TGF-b1 and are protected from bleomycin-induced pulmonary fibrosis. Primary AECs were found to produce ET-1 at physiologically active levels and increased synthesis of TGF-b1 and the induction of EMT in AECs (11). The fibrosis of IPF occurs only in the lung, is the major source of surfactant proteins (SPs), such as SP-C. This protein appears vulnerable to mutations that disrupt folding and secretion. Recent studies found that IPF patients carry increased number of apoptotic cells in alveolar and bronchial epithelia. The bleomycin mouse model supports an hypothesis that inhibition of epithelial cell apoptosis prevents the development of the fibrosis (1).

  • Interstitial pulmonary fibrosis (IPF)

IPF is the most common variety of lung fibrosis and carries a sobering mortality approaching 50% at 3–4 years (7). Increased oxidative DNA damage is seen in IPF, silicosis, and asbestosis patients, as well in experimental animal models. Ras-related C3 botulinum toxin substrate 1 (Rac1), is a protein encoded by the RAC1 gene found in human cells, which has a variety of alternatively spliced versions of the Rac1 protein (13). The UPR is activated in AT2 cells and induces epithelial–mesenchymal transformation, extracellular matrix production, and type II cell apoptosis In mutant surfactant protein C–induced interstitial pulmonary fibrosis (IPF) (10). The fibrotic phenotype of activated myofibroblasts show inhibition of the ER stress-induced IRE1a signaling pathway by using the inhibitor 4l8C that blocks TGFb-induced activation of myofibroblasts in vitro (13). IRE1a cleaves miR-150 releasing the suppressive effect that miR-150 exerts on aSMA expression through c-Myb. It also blocks ER expansion through an XBP-1-dependent pathway. In addition, prominent expression of UPR markers in AECs has been shown in the lungs of patients with surfactant protein C (SFTPC) mutation-associated fibrosis (14). Patients without SFTPC mutations with familial interstitial pneumonia and patients with sporadic IPF had selective UPR activation of AECs lining areas where there was fibrotic remodeling.
Activation of the UPR pathways may result from altered surfactant protein processing or chronic herpesvirus infection.

Fibroblasts in fibroblastic foci of IPF showed immunoreactivity for GRP78. In addition, TGF-b1 increased expression of GRP78, XBP-1, and ATF6a, which was accompanied by increases in a-SMA and collagen type I expression in mouse and human fibroblasts (15). TGF-b1–induced UPR and a-SMA and collagen type I induction were suppressed by the 4-PBA chaperone. Therefore, UPR is involved in myofibroblastic differentiation during fibrosis.

Initial observations linking ER stress and IPF were made in cases of familial interstitial pneumonia (FIP), the familial form of IPF, in a family with a mutation in surfactant protein C (SFTPC). ER stress markers are highly expressed in the alveolar epithelium in IPF and FIP (15). ER stress is induced in the alveolar epithelium predisposed to enhanced lung fibrosis after treatment with bleomycin, which is mediated at least in part by increased alveolar epithelial cell (AEC) apoptosis. In another study, aged mice developed greater ER stress in the AEC population linked to MHV68 infection as a result of increased BiP expression and increased XBP1 splicing, as well as increased AEC apoptosis, compared with young mice (16).

 

Chronic Obstructive Lung Disease (COPD)

Inflammatory and infectious factors are present in diseased airways that interact with G-protein coupled receptors (GPCRs), such as purinergic receptors and bradykinin (BK) receptors, to stimulate phospholipase C [PLC]. This is followed by the activation of inositol 1,4,5-trisphosphate (IP3)-dependent activation of IP3 channel receptors in the ER, which results in channel opening and release of stored Ca2+ into the cytoplasm. When ER Ca2+ stores are depleted a pathway for Ca2+ influx across the plasma membrane is activated. This has been referred to as “capacitative Ca2+ entry”, and “store-operated calcium entry” (3). In the next step PLC mediated Ca2+ i is mobilized as a result of GPCR activation by inflammatory mediators, which triggers cytokine production by Ca2+ i-dependent activation of the transcription factor nuclear factor kB (NF-kB) in airway epithelia. Ca2+ binding proteins including calmodulin, protein kinases C (PKCs) and the phosphatidylinositol 3-kinase (PI3K) can link Ca2+ i mobilization to NF-kB activation. Ca2+ i from ER Ca2+ release and/or a Ca2+ influx through the plasma membrane can be sensed by Ca2+ binding proteins (3). Chronically infected/inflamed native human bronchial epithelia exhibit UPR activation-dependent XBP-1 mRNA splicing and ER Ca2+ store expansion.

Protein secretion can constitute an irreversible loss of amino acids into the extracellular environment and produce net loss of equivalents from the cell. The greater the secretory burden, the greater the loss of amino acids and reducing equivalents from the cell. Activation of the UPR results in accumulation of ROS in PERK knockout cells. ATF4(-/-) and PERK (-/-) knockout cells require amino acid and cysteine supplementation to replenish amino acids lost during secretion. ATF4 would be required to induce the transcription of genes involved in amino acid import, glutathione biosynthesis and resistance to oxidative stress (3). Oxidative stress is a hallmark of CF airways disease and ATF4-induced amino acid transport is necessary for a protective role in inflamed CF airway epithelia.

Airway epithelial infection/inflammation induces ER stress-dependent activation of UPR-mediated ER Ca2+ store expansion (via XBP-1 mRNA splicing). The airway epithelial ER Ca2+ store is beneficial to the clearing of infection in normal airways. Epithelial ER Ca2+ store expansion-mediated amplification of airway inflammation may not be adequate for cystic fibrosis (CF) and COPD airways (3).

Changes in phosphor-eIF2a and CHOP expression correlate directly with the severity of airflow obstruction in COPD (10). An increase in CHOP in COPD was associated with increases in caspase 3 and 7, suggesting that the PERK pathway was contributing to heightened apoptosis in COPD. Mucous hypersecretion contributes to symptomatology and morbidity in COPD. IRE1b expression in airway epithelial cells promotes mucus cell development and mucin production.

 

Cigarette Smoke and COPD

Cigarette smoking is the major cause of COPD and accounts for more than 95% of cases in industrialized countries. It is the third largest cause of death in the world. It is now well established that cardiovascular -related comorbidities such as stroke contribute to morbidity and mortality in COPD (18). COPD involves chronic obstructive bronchiolitis with fibrosis, obstruction of small airways, emphysema with enlargement of airspaces, destruction of lung parenchyma, and loss of lung elasticity and closure of small airways. Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and loss of lung function (18). Chronic obstructive bronchiolitis, emphysema and mucus plugging are all characteristic features.

Proteomes of lung samples were taken from chronic cigarette smokers. There were 26 differentially expressed proteins (20 were up-regulated, 5 were down-regulated, and 1 was detected only in the smoking group) compared with nonsmokers. Several UPR proteins were up-regulated in smokers compared with nonsmokers and ex-smokers, including the chaperones, glucose-regulated protein 78 (GRP78) and calreticulin; a foldase, protein disulfide isomerase (PDI), and enzymes involved in antioxidant defense (18). Indeed, a UPR response in the human lung occurs in cigarette smoking that is rapid in onset, concentration dependent, and may be partially reversible with smoking cessation.
Of the proteins reported in chronic smokers, four are involved in translation and ribosome formation (60S acidic ribosomal protein P2, heat shock protein 27, and elongation factors-1b and -1d). Heat shock protein 27 inhibits formation of the large and small ribosomal complex, and 60S acidic ribosomal protein P2 associates with elongation factor-2 to form the large and small ribosomal complex. Glyceraldehyde-3-phosphate dehydrogenase, malate dehydrogenase, and ATP synthase subunit beta were up-regulated, and the inflammatory protein S100-A9/calgranulin C, an EF hand calcium-binding protein, was down-regulated (19).

Conclusion

The current status of a consolidated view of chronic pulmonary fibrotic diseases could not have been envisioned in a 19th century scientific framework. There was no scientific guideline for constructing such a perspective. I have written this perspective on lung diseases keeping in memory the contributions of my mentor, Averill A. Liebow. I have not included pulmonary carcinoma in this discussion, although it too has a place. It was in 1927 that Otto Warburg conducted his historic work with rediscovery of the observation of Louis Pasteur more than a half century earlier in his observation of aerobic glycolysis in cancer cells. The mitochondrion was not known then, which he referred to as “grana”. There was no clear mechanism for such a phenomenon. This discussion based on a growing body of work brings greater clarity to the relationship between lung development, the aging of pulmonary tissue, and the process of tissue remodeling, with a more unified view of pulmonary degeneration that even applies to pulmonary hypertension.

 

References

  1. The epithelium in idiopathic pulmonary fibrosis: breaking the barrier. A Camelo, R Dunmore, MA Sleeman and DL Clarke. Front in Pharm Jan2014; 4(173). doi: 10.3389/fphar.2013.00173

 

  1. Endoplasmic reticulum stress signaling: the microRNA connection. M Maurel and E Chevet. Am J Physiol Cell Physiol 2013; 304: C1117–C1126. doi:10.1152/ajpcell.00061.2013

 

  1. Endoplasmic Reticulum Stress in Chronic Obstructive Lung Diseases. CMP Ribeiro and WK O’Neal. Current Molec Med 2012; 12(7).

 

  1. Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease

GS Hotamisligil. Cell 2010 Mar; 140: 900–917. DOI 10.1016/j.cell.2010.02.034

 

  1. Induction of the unfolded protein response by cigarette smoke is primarily an activating transcription factor 4-C/EBP homologous protein mediated process. P Geraghty, A Wallace, JM D’Armiento. Int J COPD 2011; 6: 309–319. DOI: 10.2147/COPD.S19599

 

  1. COPD and stroke: are systemic inflammation and oxidative stress the missing links?

V Austin, PJ Crack, S Bozinovski, AA Miller and R Vlahos. Clinical Science 2016; 130: 1039–1050.

doi: 10.1042/CS20160043.

 

  1. The Role of Mitochondrial DNA in Mediating Alveolar Epithelial Cell Apoptosis and Pulmonary Fibrosis. Seok-Jo Kim, P Cheresh, RP Jablonski, DB Williams and DW Kamp. Int. J. Mol. Sci. 2015; 16: 21486-21519. http://dx.doi.org:/10.3390/ijms160921486

 

  1. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. K Ishikawa, K Takenaga, …, H Imanishi, K Nakada, Y Honma, J Hayashi. Science 2008, 320, 661–664.

 

  1. Mitochondria in lung biology and pathology: More than just a powerhouse. PT Schumacker, MN Gillespie, K Nakahira, AM Choi, ED Crouser, CA Piantadosi, & J Bhattacharya. Am. J. Physiol. Lung. Cell Mol. Physiol. 2014, 306, L962–L974.

 

  1. The Unfolded Protein Response in Chronic Obstructive Pulmonary Disease. SG Kelsen. Ann Am Thorac Soc Apr 2016; 13(S2): S138–S145. DOI: 10.1513/AnnalsATS.201506-320KV

 

  1. Epithelial fibroblast triggering and interactions in pulmonary fibrosis. PW Noble. Eur Respir Rev 2008; 17: 109: 123–129. DOI: 10.1183/09059180.00010904.

 

  1. Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis. Q Ye, Y Dalavanga, N Poulakis, SU Sixt, J Guzman and U Costabel. Eur Respir J 2008; 31: 1030–1036. DOI: 10.1183/09031936.00125407

 

  1. https://en.wikipedia.org/wiki/RAC1

 

  1. Endoplasmic reticulum stress enhances fibrosis through IRE1a-mediated degradation of miR-150 and XBP-1 splicing. F Heindryckx, F Binet, M Ponticos, K Rombouts, J Lau, J Kreuger & P Gerwins. EMBO Mol Med 2016; 8(7): 729–744. DOI 10.15252/emmm.201505925.

 

  1. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. WE Lawson, PF Crossno, VV Polosukhin, J Roldan, Dong-Sheng Cheng, et al. Am J Physiol Lung Cell Mol Physiol 294: L1119–L1126, 2008. doi:10.1152/ajplung.00382.2007

 

  1. Involvement of Endoplasmic Reticulum Stress in Myofibroblastic Differentiation of Lung Fibroblasts. HA Baek, DS Kim, HS Park, KY Jang, MJ Kang, et al. Am J Respir Cell Mol Biol 2012 Jun; 46:731–739. DOI: 10.1165/rcmb.2011-0121OC.

 

  1. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. H Tanjore, TS Blackwell and WE Lawson. Am J Physiol Lung Cell Mol Physiol 302: L721–L729, 2012. doi:10.1152/ajplung.00410.2011.

 

  1. COPD and stroke: are systemic inflammation and oxidative stress the missing links? V Austin, PJ Crack, S Bozinovski, AA Miller and R Vlahos. Clinical Science 2016; 130: 1039–1050. doi: 10.1042/CS20160043

 

  1. Cigarette Smoke Induces an Unfolded Protein Response in the Human Lung – A Proteomic Approach. SG Kelsen, X Duan, R Ji, O Perez, C Liu, and S Merali. Am J Respir Cell Mol Biol 2008; 38: 541–550. DOI: 10.1165/rcmb.2007-0221OC

 

 

 

 

 

 

Cause of Alzheimer’s Discovered: protein SIRT6 role in DNA repair process – low levels enable DNA damage accumulation

Reporter: Aviva Lev-Ari, PhD, RN

 

According to lead author Dr. Deborah Toiber of the BGU Department of Life Sciences, “If a decrease in SIRT6 and lack of DNA repair is the beginning of the chain that ends in neurodegenerative diseases in seniors, then we should be focusing our research on how to maintain production of SIRT6 and avoid the DNA damage that leads to these diseases.”

Publications

Neuroprotective functions for the histone deacetylase SIRT6

Shai Kaluski Miguel Portillo, Antoine Besnard, Daniel Stein, Monica Einav, Lei Zhong, Uwe Ueberham, Thomas Arendt, Raul Mostoslavsky, Amar Sahay, Debra Toiber

Cell Reports 2017 Mar 28;18(13):3052-3062

Long noncoding RNA: noncoding and not coded.

Toiber D, Leprivier G, Rotblat B.

Cell Death Discov. 2017 Jan 9;3:16104. doi: 10.1038/cddiscovery.2016.104.

SIRT6 recruits SNF2H to DNA break sites, preventing genomic instability through chromatin remodeling.

Toiber D, Erdel F, Bouazoune K, Silberman DM, Zhong L, Mulligan P, Sebastian C, Cosentino C, Martinez-Pastor B, Giacosa S, D’Urso A, Näär AM, Kingston R, Rippe K, Mostoslavsky R.

Mol Cell. 2013 Aug 22;51(4):454-68. doi: 10.1016/j.molcel.2013.06.018.

The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.

Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, Cosentino C, Greenson JK, MacDonald AI, McGlynn L, Maxwell F, Edwards J, Giacosa S, Guccione E, Weissleder R, Bernstein BE, Regev A, Shiels PG, Lombard DB, Mostoslavsky R.

Cell. 2012 Dec 7;151(6):1185-99. doi: 10.1016/j.cell.2012.10.047.

Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor.

Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, Zhong L, D’Urso A, Toiber D, Mostoslavsky R, Dresner-Pollak R.

Endocrinology. 2011 Dec;152(12):4514-24. doi: 10.1210/en.2011-1128.

Characterization of nuclear sirtuins: molecular mechanisms and physiological relevance.

Toiber D, Sebastian C, Mostoslavsky R.

Handb Exp Pharmacol. 2011; 206:189-224. doi: 10.1007/978-3-642-21631-2_9.

A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development.

Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, Toiber D, Kulkarni M, Wang Q, Najafi-Shoushtari SH, Mostoslavsky R, Gygi SP, Gill G, Dyson NJ, Näär AM.

Mol Cell. 2011 Jun 10;42(5):689-99. doi: 10.1016/j.molcel.2011.04.020.

Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.

Toiber D, Azkona G, Ben-Ari S, Torán N, Soreq H, Dierssen M.

Neurobiol Dis. 2010 Oct;40(1):348-59. doi: 10.1016/j.nbd.2010.06.011.

Acetylcholinesterase variants in Alzheimer’s disease: from neuroprotection to programmed cell death.

Greenberg DS, Toiber D, Berson A, Soreq H.

Neurodegener Dis. 2010;7(1-3):60-3. doi: 10.1159/000285507.

The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha.

Zhong L, D’Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, Mostoslavsky R.

Cell. 2010 Jan 22;140(2):280-93. doi: 10.1016/j.cell.2009.12.041.

Pro-apoptotic protein-protein interactions of the extended N-AChE terminus.

Toiber D, Greenberg DS, Soreq H.

J Neural Transm 2009 Nov;116(11):1435-42. doi: 10.1007/s00702-009-0249-2.

N-acetylcholinesterase-induced apoptosis in Alzheimer’s disease.

Toiber D, Berson A, Greenberg D, Melamed-Book N, Diamant S, Soreq H.

PLoS One. 2008 Sep 1;3(9):e3108. doi: 10.1371/journal.pone.0003108.

A novel isoform of acetylcholinesterase exacerbates photoreceptors death after photic stress.

Kehat R, Zemel E, Cuenca N, Evron T, Toiber D, Loewenstein A, Soreq H, Perlman I.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1290-7.

Modulated splicing-associated gene expression in P19 cells expressing distinct acetylcholinesterase splice variants.

Ben-Ari S*, Toiber D*, Sas AS, Soreq H, Ben-Shaul Y.

J Neurochem. 2006 Apr;97 Suppl 1:24-34.

  • ​*Equal contribution

Cellular stress reactions as putative cholinergic links in Alzheimer’s disease.

Toiber D, Soreq H.

Neurochem Res. 2005 Jun-Jul;30(6-7):909-19.

Function of alternative splicing.

Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj TA, Soreq H.

Gene. 2005 Jan 3;344:1-20.

Combinatorial complexity of 5′ alternative acetylcholinesterase transcripts and protein products.

Meshorer E, Toiber D, Zurel D, Sahly I, Dori A, Cagnano E, Schreiber L, Grisaru D, Tronche F, Soreq H.

J Biol Chem. 2004 Jul 9;279(28):29740-51.

SOURCE

https://toiber.wixsite.com/toiber-lab/publications

The Future of Hospitals – How Medical Care and Technology Work Together to Advance Patient Care 

Curator: Gail S. Thornton, M.A.

Co-Editor: The VOICES of Patients, Hospital CEOs, HealthCare Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

 

Gap Medics (https://www.gapmedics.com/blog/), the world’s leading provider of hospital work experience placements for high school and university students, recently released their “Futuristic Hospitals” infographic. The infographic reviews a collection of top hospitals in the world based on several key factors:

  • overall patient care,
  • innovative medical and technological excellence,
  • efforts toward sustainability,
  • environmental stewardship, and
  • social responsibility, as well as
  • other innovative health care features

to help advance the field of medicine and, ultimately, patient care.

Futuristic Hospitals Infographic

Image SOURCE: Infographic of Futuristic Hospitals courtesy of Evolved Digital and Gap Medics. Reprinted here with Permission from the Source.

 

“Many leading hospital facilities are now rolling out significant improvements and changes that couldn’t have been envisioned 10 years ago,” said Ian McIntosh, Director, Evolved Digital (http://evolveddigital.co.uk/), a U.K.-based digital marketing company specializing in search engine optimization and content marketing, whose team created the infographic for Gap Medics.

Science and innovation are working together to help convey higher expectations for quality medical and health care and advancements in the hospital experience for health care providers, patients and their families.

Particularly, the infographic analyzed prominent hospitals around the world so patients and their families can learn about the latest advances and efforts in patient care and hospital and medical technology.

In this infographic, we investigated the most cutting-edge hospital facilities in the world, where best-in-class technology and innovative medical care are making a difference in providing a quality experience all over the world.

“Gap Medics creates programs offered to thousands of students from Europe, Asia and the United States so they have the opportunity to gain insights into the work of doctors, nurses, physician assistants, midwives and dentists before the students begin their clinical training,” said Dave Brown, Director, Gap Medics, a U.K.-based company that provides hospital work experience between 1-8 weeks to students 16 years of age and older.

This one-in-a-lifetime opportunity helps students better understand their chosen career path, develop as people, and strengthen their university application process.

 

REFERENCE/SOURCE

http://evolveddigital.co.uk/

https://www.gapmedics.com/blog/2017/03/27/futuristic-hospitals/

Other related articles published in this Open Access Online Scientific Journal include the following:

 

“Sudden Cardiac Death,” SudD is in Ferrer inCode’s Suite of Cardiovascular Genetic Tests to be Commercialized in the US

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/02/10/sudden-cardiac-death-sudd-is-in-ferrer-incodes-suite-of-cardiovascular-genetic-tests-to-be-commercialized-in-the-us/

 

Hybrid Cath Lab/OR Suite’s da Vinci Surgical Robot of Intuitive Surgical gets FDA Warning Letter on Robot Track Record

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/07/19/hybrid-cath-labor-suites-da-vinci-surgical-robot-of-intuitive-surgical-gets-fda-warning-letter-on-robot-track-record/

 

3D Cardiovascular Theater – Hybrid Cath Lab/OR Suite, Hybrid Surgery, Complications Post PCI and Repeat Sternotomy

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/07/19/3d-cardiovascular-theater-hybrid-cath-labor-suite-hybrid-surgery-complications-post-pci-and-repeat-sternotomy/

Tweets HIGHLIGHTS from 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge

Curator: Aviva Lev-Ari, PhD, RN

 

 @pharma_BI @AVIVA1950 @USAIC 

USAIC Retweeted your Tweet

11h11 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Amrit Ray, CMO, Janssen In India, what is the philosophy on alignment FDA, other regulatory

9 other Retweets

Adam Pulwer Retweeted your reply

11h11 hours ago

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. James Bradner, Novartis, active in CRISPR, technology from outside invited in

iboss liked your reply

 

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. William Chin, Executive Vice President and CMO, PhRMA Patient’s Compliance, control investigation

 

Publicity.ai liked your reply

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. William Chin, Executive Vice President and CMO, PhRMA HOW to reduce Failure in Trials??

Dan Nedelko liked your reply

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. Michael Rosenblatt, CMO, Flagship Pioneering, Right to TRY, does that exist in India?

  1. Genomics Press liked your replies

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Dr. Richard Moscicki, USFDA Frequensist Analysis at FDA, Precision medicine requires Bayesian approach

1 other like

Zeal Caiden liked your reply

 

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Amrit Ray, CMO, Janssen In India, what is the philosophy on alignment FDA, other regulatory

  1. USAICRetweeted your Tweet

 

May 18

Aviva Lev-Ari @AVIVA1950

@pharma_BI @AVIVA1950 @USAIC #USAIC17 Panel on Vaccines – How do we make Vaccines more affordable for Populations, oral and stable

1 other Retweet

 

Retweeted

several companies are chasing ONE molecule, the same one

Retweeted

Vaccines Dr. Stephen Caddick, Wellcome Trust, use vaccine to mitigate bacterial resistance

Retweeted

Panel on Vaccines – How do we make Vaccines more affordable for Populations, oral and stable

Retweeted

We start NOW LIVE REAL TIME – 11th US-India BioPharma &amp; Healthcare Summit, 5/18 Marriott Cambridge

Vaccines Dr. Stephen Caddick, Wellcome Trust, use vaccine to mitigate bacterial resistance

Panel on Vaccines – How do we make Vaccines more affordable for Populations, oral and stable

LIVE – 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway,…

LIVE 11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway, Cambridge

Reporter: Aviva Lev-Ari, PhD, RN

Aviva Lev-Ari, PhD, RN at LPBI Group will cover the event in Real Time

@pharma_BI

@AVIVA1950

@USAIC

11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway, Cambridge

BioPharma & Healthcare Summit 2017

Emcee – Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda

* Speakers and Timings subject to change

Time Topic
8-45 AM – 9-15 AM Registration and Networking
9-15 AM – 9-30 AM Welcome address by Karun Rishi, President, USA-India Chamber of Commerce

Opening comments by – Dr Andrew Plump, Chief Medical & Scientific Officer, Member of the Board of Directors, Takeda Pharmaceuticals

  1. Value and Access in Healthcare vs Innovations, Patients,
  2. Value in HealthCare is relative to time and location
  3. massive underserved population
  4. Access: whoever Patients are and whereever they are
  5. In India 1.3 Billion people, 70% of World population and HealthCare spending is 1% of World cost of HealthCare – need for investment ans development of infrastructure
9-30 AM – 9-55 AM India Regulatory and Clinical Research Update*
Dr. R.K. Vats , IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India
9-55 AM – 10-45 AM Panel Discussion: Oncology

  1. Immunotherapy – Tumor cells, necrosis, mutation, Response to T-Cell therapy and Tumor shrinkage
  2. What is the mechanism to enable Oncology drugs in China and India
  3. Oncology Drug are two expensive
  4. Melanoma gets best response to PD-1
  5. We might not have found the right Checkpoint molecule, new agonist therapies, new antigens
  6. Oncolytic Viruses – for tumors that do not respond to immuno therapy
  7. Combination therapy, increase in Toxicity
  8. Toxicity – Cerebral edema during clinical trials of immunotherapy
  9. Upregulation and Downregulation dependent on dosing in immuno-therapy

Panelists:

  • Dr. Edward Benz, President & CEO Emeritus, Dana Farber Cancer Institute
    1. Durable response, immuno-suppression, biological role in tumor surveillence, Checkpoint opens up the use of vaccines
    2. Block of 50 molecules
    3. How can we learn more on the Translational and Clinical level – getting smarter – HOW
    4. Screening Patients: Immuno-phynotyping, predicting markers,
  • Dr. Rakesh Jain, E.L. Steele Laboratory of Tumor Biology,  MGH Cancer Center/ Harvard Medical School
  • Dr. Timothy Clackson, President R&D and CSO, Ariad Pharmaceuticals
  • Dr. Chandru, Chairman, Strand Life Sciences
  1. Licensing HepC will be very important
  • Dr. Jeffrey Engelman, Global Head of Oncology Research, Novartis Institutes for BioMedical Research
  1. PD-1 is $50,000 a year therapy, In India affordable pricing
  2. Collaboration: PACK –  few companies and Academic – focus on immunotherapy,
  3. Foundation Medicine biomarkers Platform
  4. What is the mutation burden which will predict the response to PD-1

 

Moderator:
Dr. Vijay Kuchroo, Director- Evergrande Center for Immunologic Diseases, Brigham & Women’s Hospital/ Harvard Medical School

10-45 AM – 11-15 AM *Fireside Chat on Govnt’t Agency, Advocacy Groups, Big Phara, NIH, FDA

  • Dr. Richard Moscicki, ex-Genzyme, Deputy Director (Science Operations), Center for Drug Evaluation and Research, USFDA and
  1. Since 2004, 40 Public-Private Partnerships, relationships with NIH
  2. External relationships, where are the Scientists going,
  3. Toxicology, Biomarkers, Lexicon,
  • Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, NIH
  1. Academic and Biotech companies relations: Toxicity testing, new clinical trial design, increase efficiency
  2. Knowledge of disease increased vastly
  3. HealthCare not at the same rate
  4. Rare disease tested on 5,000 patients, Genomics combinatories
  5. Clinical Trial Templets: FDA & NIH working together on
  6. FDA & DARPA – Tissue engineering
  7. mainatin Statistical Robustness yet change the process
  • Dr. R.K. Vats , IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India

 

  • Moderator:
    Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA
  1. Efficiency of Clinical Trial needs improvement
  2. Gene therapy in US: Interaction between NIH and FDA – how is it going
11-15 AM -11-45 AM Networking & Tea Break
11-45 AM – 12-35 PM Panel Discussion: Vaccines

Panelists:

  • Dr. Stephen Caddick, Director of Innovation, Wellcome Trust
  1. management health in decline
  2. scientific complexity
  3. Science, Technology and Understanding Human Behavior neede NOT to fail society
  • Dr. Johan Van Hoof, Global Therapeutic Head- Infectious Diseases & Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Dr. Gagandeep Kang, Executive Director, Translational Health Science & Technology Institute (THISTI)
  1. Clinical Trial Design in India, integrated IRB system for evaluation
  • Michael Nally, President, Merck Vaccines, Merck & Co.
  • Dr. Niranjan Sardesai, Chief Operating Officer, Inovio Pharmaceuticals

Moderator:
Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA

  1. Necessary expertise on emerging infectious agents
  2. Affordability of Vaccine
  3. More discussion needed on Vaccines
12-35 PM – 1-05 PM Fireside Chat with

  • Sanat Chattopadhyay, President, Merck Manufacturing Division, Merck & Co.;
  • Dr. R. K. Vats, IAS, Additional Secretary, Ministry of Health and Family Welfare, Government of India; Alok Kumar, Advisor, Niti Aayog*

Moderator:
Dr. Amrit Ray, Chief Medical Officer, Janssen Pharmaceutical Companies of Johnson & Johnson

1-05 PM – 2-40 PM Luncheon Panel Discussion: Clinical Trials & Regulatory

Panelists:

    • Dr. Richard Moscicki, Deputy Director (Science Operations), CDER, USFDA
    • Dr. Petra Kaufmann, Director, Office of Rare Diseases Research & Director, Division of Clinical Innovations – NCATS, NIH
    • Dr. G.N. Singh, Drug Controller General of India, Central Drugs Standard Control Organization, Ministry of Health
    • K.V. Subramaniam, President, Reliance Life Sciences
  • Dr. William Chin, Executive Vice President and Chief Medical Officer, PhRMA
  1. Patient’s Compliance, control investigation
  2. Value to Patient, what value do they ask for

Moderator:
Dr. Michael Rosenblatt, Chief Medical Officer, Flagship Pioneering

2-40 PM – 3-15 PM Networking & Tea Break
3-15 PM – 4-05 PM Panel Discussion: Rare & Neglected Diseases

Panelists:

  • Dr. Chris Austin, Director, National Center for Advancing Translational Sciences, National Institutes of Health
  • Dr. Jim Burns, President and CEO, Casebia Therapeutics
  • Dr David Meeker, Executive Vice President & Head, Sanofi Genzyme
  • Dr. Wim Parys, Head of R&D- Global Public Health, Janssen Pharmaceutical companies of Johnson & Johnson
  • Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen

Moderator:
Dr. Steve Uden, Head of Research, Alexion Pharmaceuticals

4-05 PM – 4-55 PM Panel Discussion: Drug Discovery and Development

Panelists:

  • Dr. James Bradner, President, Novartis Institutes for BioMedical Research
  • Dr. William Hait, Global Head- Research & Development, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Dr Andrew Plump, Chief Medical & Scientific Officer and Director, Takeda Pharmaceuticals
  1. Clinical Partnerships important, last molecule developed in house in 1999, Partnershiip in Stem Cells, development for Ciliac disease
  • Dr. David Nicholson, Chief R&D Officer, Allergan
  1. R&D is small Intell Group to identify opportunities is large, 2,500

Moderator:
Dr. Martin Mackay, Executive Vice President and Global Head of R&D, Alexion Pharmaceuticals

4-55 PM – 5-00 PM Closing Remarks
5-00 PM – 6-30 PM Cocktails & Networking Reception

SEE OUR NEW CANCER BOOK ON AMAZON.com

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

Two Connectionists and Two Conversationalists – Brain Science is the Expertise of First-term incoming President of Hebrew University of Jerusalem and Third-term President of Technion, Israel Institute of Technology

Reporter: Aviva Lev- Ari, PhD, RN

Article ID #237: Two Connectionists and Two Conversationalists – Brain Science is the Expertise of First-term incoming President of Hebrew University of Jerusalem and Third-term President of Technion, Israel Institute of Technology. Published on 5/17/2017

WordCloud Image Produced by Adam Tubman

Two Connectionists and Two Conversationalists

Professor Asher Cohen, was elected President of the Hebrew University of Jerusalem

Reporter: Aviva Lev-Ari, PhD, RN

Prof. Peretz Lavie – CV

Prof. Peretz Lavie is the 16th president of Technion – Israel Institute of Technology, having taken the position on October 1, 2009.  Between 1993 and 1999, Prof. Lavie served as dean of the Rappaport Faculty of Medicine, and between 2001 and 2008, as Technion’s vice president for resource development and external relations.

Prof. Lavie is a world-respected Lavie authority on the psychophysiology of sleep and sleep disorders. He is the author of several books, including: The Enchanted World of Sleep; and Restless Nights: Understanding Sleep Apnea and Snoring. He has founded several start-up companies, including Itamar Medical Ltd.

http://pard.technion.ac.il/technion-president/

President Prof. Peretz Lavie Elected to 3rd Term

During Prof. Lavie’s current term in office (2009-2017), Technion recorded impressive achievements led by the recruitment of more than 200 new faculty members. “Outstanding faculty members are the most important asset of any university,” said Prof. Lavie. “The quality of Technion and its future status will be determined first and foremost by the quality of its faculty members.”

The new faculty members, whose recruitment involved the extensive recruitment of resources, are mostly young and were selected based on excellence in research. The increase in the number of faculty members was accompanied by a significant increase in the number of publications in the world’s leading scientific journals. In 2016, Technion was ranked 26th in the world in the list of Rising Stars, published by the leading scientific journal Nature, following a 40% increase in Technion’s publications in leading scientific journals. In the Shanghai ranking, the world’s leading index of academic institutions, within eight years Technion shot up from rank 101-152 worldwide to 69th place in 2016: the top of Israel’s universities. These rankings, along with a significant increase in the awarding of research grants, attest to Technion’s academic excellence and the research achievements of its faculty members.

The Jacobs Technion-Cornell Institute – photo simulation – Credit: Morphosis [Thom Mayne]

The research world, in Prof. Lavie’s view, is changing. In the past, a scientist could carry out research and achieve breakthroughs on his own, but now significant research requires interdisciplinary cooperation. “The walls between disciplines, faculties, and fields of research are collapsing,” explains Prof. Lavie. “Future achievements in science and engineering will require cooperation between laboratories and researchers from different fields. In order to achieve significant scientific and engineering breakthroughs, enormous knowledge is now required — knowledge that an individual scientist does not possess.” For this reason, Technion has worked to establish interdisciplinary centers where researchers from different faculties work together. These centers include research institutes such as the Technion Integrated Cancer Center (TICC), the Quantum Engineering Center, the Cyber Security Research Center, and the Technion Computer Engineering Center (TCE), in addition to the Excellence Centers of the Council for Higher Education that have been established at Technion.

The number of students at Technion is growing steadily. In the past eight years, the number of students has increased from 12,665 (2009-2010) to 14,121 (2016-2017). In addition, there has been a 30% increase in the number of graduate students (master’s and doctoral).

Since taking office as President, Prof. Lavie has worked to change the atmosphere at Technion and its image as a rigid institution that is not sufficiently considerate of its students. Under his leadership, a committee was established to examine the structure of studies and academic load at Technion, headed by Prof. Yachin Cohen of the Faculty of Chemical Engineering. The committee’s recommendations, which were implemented in conjunction with the Technion Student Association (TSA), included many changes aimed at improving teaching at Technion.

In addition, in 2012 Prof. Lavie instituted the Yanai Prize for Excellence in Academic Education, with the generous donation of Technion alumnus Moshe Yanai. The prize, which is awarded in recognition and appreciation of faculty members who set an example by their contributions to teaching and learning, has already become synonymous with excellence in teaching at Technion and has been awarded to 62 faculty members and three faculties.

http://www.technion.ac.il/en/2017/05/president-prof-peretz-lavie-elected-to-3rd-term/